Evidence map›Paper›PMID 42061030›Full record

Trial reportBreast (Edinburgh, Scotland)2026

Health-related quality of life with pertuzumab retreatment: Secondary analysis of the PRECIOUS trial.

Naruto Taira, Yutaka Yamamoto, Hiroji Iwata, Shigehira Saji, Masato Takahashi, Tetsuhiro Yoshinami, Takayuki Ueno, Tatsuya Toyama, Toshimi Takano, Masahiro Kashiwaba and 7 more

Abstract readRandomized Controlled TrialClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Naruto TairaDepartment of Breast and Thyroid Surgery, Kawasaki Medical School, Kurashiki, Okayama, Japan. Electronic address: ntaira@med.kawasaki-m.ac.jp.
Yutaka YamamotoDepartment of Breast and Endocrine Surgery, Kumamoto University, Hospital, Honjo, Chuo-ku, Kumamoto, Japan.
Hiroji IwataDepartment of Advanced Clinical Research and Development, Nagoya, City University, Graduate School of Medical Science, Mizuho-cho, Mizuho-ku, Nagoya, Japan.
Shigehira SajiDepartment of Medical Oncology, Fukushima Medical University, School of Medicine, Fukushima City, Japan.
Masato TakahashiDepartment of Breast Surgery, Hokkaido University Hospital, Kitaku, Sapporo, Hokkaido, Japan.
Tetsuhiro YoshinamiDepartment of Breast and Endocrine Surgery, Osaka University, Hospital, Suita, Osaka, Japan.
Takayuki UenoBreast Surgical Oncology, Breast Oncology Center, The Cancer, Institute Hospital of JFCR, Koto-ku, Tokyo, Japan.
Tatsuya ToyamaDepartment of Breast Surgery, Nagoya City University, Mizuho-cho, Mizuho-ku, Nagoya, Japan.
Toshimi TakanoBreast Medical Oncology, Breast Oncology Center, The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan.
Masahiro KashiwabaBreast Surgery Center, Heartlife Hospital, Nakagami-gun, Okinawa, Japan.
Koichiro TsugawaDepartment of Breast and Endocrine Surgery, St. Marianna University School of Medicine, Miyamae-ku, Kawasaki, Japan.
Hiroshi TadaDepartment of Surgery, Division of Breast and Endocrine Surgery, Tohoku University Hospital, Aoba-ku, Sendai-shi, Miyagi, Japan.
Fumikata HaraDepartment of Breast Oncology, Aichi Cancer Center Hospital, Chikusa-ku, Nagoya, Japan.
Tomomi FujisawaDepartment of Breast Oncology, Gunma Prefectural Cancer Center, Takahayashinishicho Ota, Gunma, Japan.
Naoki NiikuraDepartment of Breast Surgery, Tokai University Hospital, Isehara-shi, Kanagawa, Japan.
Satoshi MoritaDepartment of Biomedical Statistics and Bioinformatics, Kyoto, University Hospital, Shogoin Sakyo-ku, Kyoto, Japan.
Norikazu MasudaBreast Surgery, Graduate School of Medicine, Kyoto University, Shogoin Sakyo-ku, Kyoto, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRetreatment with pertuzumab has demonstrated survival benefit in previously treated human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer, but its effect on health-related quality of life (HRQoL) is not well established.

methodsThis secondary analysis of the randomized, open-label phase III PRECIOUS trial evaluated HRQoL in women previously treated with pertuzumab, trastuzumab, and chemotherapy. Patients were randomized 1:1 to pertuzumab plus trastuzumab plus chemotherapy (PTC) or trastuzumab plus chemotherapy (TC). HRQoL was assessed using the Functional Assessment of Cancer Therapy-Breast (FACT-B). The primary endpoint was time-to-deterioration (TTD) in the Breast-Trial Outcome Index (B-TOI), defined as a ≥5-point decline. Secondary endpoints included TTD in the FACT-B total score, General Subscale, and Breast Cancer Subscale. Longitudinal changes were analyzed using linear mixed-effects models.

resultsOf 217 eligible patients, 178 were included in the HRQoL analysis (median age: 57 years in PTC and 60 years in TC). No significant between-group differences in TTD for B-TOI were observed (hazard ratio, 1.22; 95% CI, 0.86-1.90; p = 0.23). Secondary TTD endpoints also showed no differences. Mixed-effects models indicated that TC had better B-TOI and Breast Cancer Subscale scores at week 6, but these early differences were not sustained beyond week 12.

conclusionPertuzumab retreatment was not associated with clinically meaningful deterioration in HRQoL. These findings support the use of dual HER2 blockade beyond progression in appropriately selected patients.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsQuality of LifeAdultAgedErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedRetreatmentTrastuzumabTreatment OutcomeAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalERBB2 protein, humanErb-b2 Receptor Tyrosine KinasespertuzumabTrastuzumabDual HER2 blockadeFunctional assessment of cancer therapy-breast (FACT-B)Health-related quality of lifeHER2-Positive breast cancerMetastatic breast cancerPertuzumab retreatmentTime-to-deterioration

Identifiers

PMID42061030
PMCPMC13141780

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.